New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Organon presented a post hoc analysis of Phase 3 ADORING 1 and 2 trial data showing VTAMA cream achieved early and consistent improvements in atopic dermatitis across pediatric and adult age groups. Patients aged 2-6 years demonstrated a 70.2% EASI75 response rate at week 8 compared to 20.5% for vehicle, with significant improvements observed as early as week 2 across all cohorts.
Key figures
- Drug Name
- VTAMA (tapinarof)
- Phase Of Trial
- Phase 3
- Total patients n
- 813
- Easi75 response adults
- 50.8%
- Viga ad response adults
- 38.0%
- Treatment duration weeks
- 8
- Easi75 response 2 6 years
- 70.2%
- Easi75 response 7 11 years
- 53.6%
- Viga ad response 2 6 years
- 56.3%
- Easi75 response 12 17 years
- 62.2%
- Viga ad response 7 11 years
- 44.9%
- Viga ad response 12 17 years
- 48.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.